Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4337713 · 1 trial · 7 indications
Per investigator assessed Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| LY4337713 (Cohort A1) | EXPERIMENTAL | Escalating doses of LY4337713 administered intravenously (IV). |
| LY4337713 (Cohort A2) | EXPERIMENTAL | Two or more dose regimens of LY4337713 (evaluated during dose escalation) administered IV. |
| Experimental: LY4337713 (Cohort B) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| Experimental LY4337713 (Cohort C) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| Experimental: LY4337713 (Cohort D) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| LY4337713 (Cohort E) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| Name | Type | Description |
|---|---|---|
| LY4337713 | DRUG | Administered IV. |
Inclusion Criteria: * Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment * Must have histologically or cytologically confirmed diagnosis of one of the following: * Adenocarcinoma of the pancreas * Hormone receptor (HR)-positive human e...
LY4337713 is an investigational small molecule being studied for the treatment of ovarian neoplasms and other FAP-positive solid tumors. It is in Phase 1 clinical development and is not yet approved for any indication. Eli Lilly and Company is developing the drug for biomarker-selected cancer patients.
LY4337713 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the ongoing Phase 1 clinical trial evaluating the drug in patients with FAP-positive solid tumors.
LY4337713 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The single ongoing trial is currently recruiting participants.
LY4337713 is being evaluated in one clinical trial, NCT07213791, titled A Study of LY4337713 in Participants With FAP-Positive Solid Tumors. The trial is recruiting and has an estimated enrollment of 241 participants across the United States, China, Germany, Japan, and the Netherlands.
LY4337713 is being studied in FAP-positive solid tumors, including ovarian neoplasms, breast neoplasms, pancreatic intraductal neoplasms, colorectal neoplasms, esophageal neoplasms, stomach neoplasms, and cholangiocarcinoma. The trial enrolls adults aged 18 years and older and selects patients based on a biomarker.